DK3295941T3 - Fremgangsmåde til fremstilling af form a af grapiprant - Google Patents

Fremgangsmåde til fremstilling af form a af grapiprant Download PDF

Info

Publication number
DK3295941T3
DK3295941T3 DK17193737.8T DK17193737T DK3295941T3 DK 3295941 T3 DK3295941 T3 DK 3295941T3 DK 17193737 T DK17193737 T DK 17193737T DK 3295941 T3 DK3295941 T3 DK 3295941T3
Authority
DK
Denmark
Prior art keywords
grapiprant
procedure
making
Prior art date
Application number
DK17193737.8T
Other languages
English (en)
Inventor
Tamara Newbold
Melissa Smith
Christopher Seekamp
Robert Wenslow
Xia Lu
Original Assignee
Aratana Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aratana Therapeutics Inc filed Critical Aratana Therapeutics Inc
Application granted granted Critical
Publication of DK3295941T3 publication Critical patent/DK3295941T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Led Devices (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Ceramic Products (AREA)
  • Inorganic Insulating Materials (AREA)
DK17193737.8T 2014-03-06 2015-03-05 Fremgangsmåde til fremstilling af form a af grapiprant DK3295941T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461949006P 2014-03-06 2014-03-06
US201461996961P 2014-07-30 2014-07-30
EP15758500.1A EP3113773B1 (en) 2014-03-06 2015-03-05 Crystalline forms of grapiprant

Publications (1)

Publication Number Publication Date
DK3295941T3 true DK3295941T3 (da) 2020-08-24

Family

ID=54016295

Family Applications (3)

Application Number Title Priority Date Filing Date
DK19156369.1T DK3511000T3 (da) 2014-03-06 2015-03-05 Krystallinsk form x2 af grapiprant
DK17193737.8T DK3295941T3 (da) 2014-03-06 2015-03-05 Fremgangsmåde til fremstilling af form a af grapiprant
DK15758500T DK3113773T3 (da) 2014-03-06 2015-03-05 Krystallinske former af grapiprant

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK19156369.1T DK3511000T3 (da) 2014-03-06 2015-03-05 Krystallinsk form x2 af grapiprant

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK15758500T DK3113773T3 (da) 2014-03-06 2015-03-05 Krystallinske former af grapiprant

Country Status (16)

Country Link
US (1) US9265756B2 (da)
EP (4) EP3511000B1 (da)
JP (2) JP6535683B2 (da)
KR (2) KR101697914B1 (da)
CN (11) CN107501262A (da)
AU (1) AU2015227064B2 (da)
CA (10) CA2997692A1 (da)
DK (3) DK3511000T3 (da)
ES (3) ES2919346T3 (da)
MX (2) MX367376B (da)
NZ (3) NZ733234A (da)
PL (3) PL3113773T3 (da)
PT (3) PT3295941T (da)
RU (1) RU2638931C1 (da)
TW (1) TWI537270B (da)
WO (1) WO2015134797A1 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12109218B2 (en) 2014-12-09 2024-10-08 Aratana Therapeutics, Inc. Compositions of grapiprant and methods for using the same
TWI664969B (zh) 2014-03-06 2019-07-11 雅瑞塔那醫療公司 格拉匹綸(grapiprant)組合物及其使用方法
CN112292128A (zh) 2018-04-16 2021-01-29 阿瑞斯医疗有限公司 Ep4抑制剂和其用途
US20210315909A1 (en) * 2018-07-11 2021-10-14 Arrys Therapeutics, Inc. Polymorphic compounds and uses thereof
IL280051B2 (en) * 2018-07-11 2024-03-01 Arrys Therapeutics Inc EP4 inhibitors and their synthesis
US11254675B2 (en) * 2019-08-12 2022-02-22 Cadila Healthcare Limited Process for preparation of grapiprant
WO2021226162A1 (en) 2020-05-05 2021-11-11 Arrys Therapeutics, Inc. Ep4 antagonists and their use in the treatment of proliferative diseases
CN116283959A (zh) * 2021-12-10 2023-06-23 江苏慧聚药业股份有限公司 格拉匹纶新晶型及其制备

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN2001000224A (es) 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
AU2006221699A1 (en) * 2005-03-11 2006-09-14 Pfizer Inc. Crystal forms of an imidazole derivative
EP2270000B1 (en) * 2005-05-23 2015-07-29 Novartis AG Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts
JP5069752B2 (ja) * 2006-12-15 2012-11-07 グラクソ グループ リミテッド Ep4受容体アゴニストとしてのベンズアミド誘導体
CN102149384B (zh) * 2008-08-14 2014-08-20 南京奥昭生物科技有限公司 作为ep4受体拮抗剂的杂环酰胺衍生物
CN103702995B (zh) 2011-05-18 2016-04-13 拉夸里亚创药株式会社 4-{[4-({[4-(2,2,2-三氟乙氧基)-1,2-苯并异噁唑-3-基]氧}甲基)哌啶-1-基]甲基}-四氢-2h-吡喃-4-羧酸的多晶型形式

Also Published As

Publication number Publication date
CA2997694A1 (en) 2015-09-11
NZ724923A (en) 2018-03-23
PL3295941T3 (pl) 2020-11-16
EP3511000A1 (en) 2019-07-17
CA2997697A1 (en) 2015-09-11
MX367376B (es) 2019-08-16
JP6535683B2 (ja) 2019-06-26
PT3511000T (pt) 2022-05-25
EP3113773A4 (en) 2017-05-10
US20150250774A1 (en) 2015-09-10
TWI537270B (zh) 2016-06-11
CN107400132A (zh) 2017-11-28
JP2018065819A (ja) 2018-04-26
PT3295941T (pt) 2020-08-25
WO2015134797A1 (en) 2015-09-11
CA2997746A1 (en) 2015-09-11
KR101697914B1 (ko) 2017-01-18
MX388969B (es) 2025-03-20
KR20170008889A (ko) 2017-01-24
CN110256426A (zh) 2019-09-20
CN107759590A (zh) 2018-03-06
KR101771385B1 (ko) 2017-08-24
CA2997692A1 (en) 2015-09-11
EP3295941A1 (en) 2018-03-21
CA3168877A1 (en) 2015-09-11
AU2015227064A1 (en) 2016-10-27
CA2997718A1 (en) 2015-09-11
EP3511000B1 (en) 2022-04-27
NZ733225A (en) 2018-03-23
EP3113773B1 (en) 2019-09-18
DK3113773T3 (da) 2019-11-18
CA2997694C (en) 2021-04-06
CN107540671A (zh) 2018-01-05
KR20160106779A (ko) 2016-09-12
CN107759589A (zh) 2018-03-06
CA2941019A1 (en) 2015-09-11
CN107501262A (zh) 2017-12-22
EP3520790A1 (en) 2019-08-07
AU2015227064B2 (en) 2017-05-11
US9265756B2 (en) 2016-02-23
CA3105571A1 (en) 2015-09-11
ES2919346T3 (es) 2022-07-26
CN105764508A (zh) 2016-07-13
ES2755396T3 (es) 2020-04-22
PL3511000T3 (pl) 2022-08-22
PT3113773T (pt) 2019-11-12
PL3113773T3 (pl) 2020-05-18
CN107501263A (zh) 2017-12-22
EP3113773A1 (en) 2017-01-11
CN113087705A (zh) 2021-07-09
CA2997703A1 (en) 2015-09-11
NZ733234A (en) 2018-08-31
CN107573339A (zh) 2018-01-12
ES2816057T3 (es) 2021-03-31
CA2997741A1 (en) 2015-09-11
MX2016011023A (es) 2016-11-28
CN107759591A (zh) 2018-03-06
RU2638931C1 (ru) 2017-12-19
EP3295941B1 (en) 2020-07-22
JP2017507161A (ja) 2017-03-16
TW201538500A (zh) 2015-10-16
DK3511000T3 (da) 2022-05-30

Similar Documents

Publication Publication Date Title
DK3192902T3 (da) Fremgangsmåde til fremstilling af graphenholdige viscosefibre
DK3372584T5 (da) Fremgangsmåde til fremstillingen af en diarylthiohydantoin-forbindelse
DK3096741T3 (da) Fremgangsmåde til fremstillingen af hybridosomer
DK3137169T3 (da) Hæmmere af lysin-specifik demethylase-1
DK3325443T3 (da) Fremgangsmåde til fremstilling af pridopidin
DK3152176T3 (da) Fremgangsmåde til fremstillingen af en cementforbindelse
DK3102576T3 (da) Dihydropyrrolopyridininhibitorer af ror-gamma
DK3174858T3 (da) Fremgangsmåde til fremstilling af pyrazoler
DK3160956T3 (da) Inhibitorer af lysin-specifik demethylase-1
DK3294700T3 (da) Fremgangsmåde til fremstilling af limonen-4-ol
DK3180331T3 (da) Polymorfer af selinexor
DK3511319T3 (da) Hæmmere af lysinspecifik demethylase-1
DK2953904T3 (da) Fremgangsmåde til kontrolleret fremstilling af et biocid
DK3721997T3 (da) Fremgangsmåde til fremstilling af en katalysator
DK3529233T3 (da) Fremgangsmåde til fremstilling af 3-alkylsulfanyl-2-chlor-n-(1-alkyl-1h-tetrazol-5-yl)-4-trifluoromethyl-benzamider
DK3233813T3 (da) Fremgangsmåder til fremstilling af oxathiazin-lignende forbindelser
DK3277915T3 (da) Fremgangsmåde til nedlukning af en brøn
DK3229995T3 (da) Fremgangsmåde for fremstilling af et endestykke
DK3156539T3 (da) Kontinuerlig fremgangsmåde til forbehandling af et ligno-celluloseholdigt råmateriale
DK3262023T3 (da) Fremgangsmåde til fremstillingen af diener
DK3137449T3 (da) Fremgangsmåder til fremstilling af substituerede cycloseriner
DK3418273T3 (da) Derivater af flavagliner
DK3511000T3 (da) Krystallinsk form x2 af grapiprant
DK3274143T3 (da) Fremgangsmåde til fremstilling af lignocellulosematerialer
DK3387086T3 (da) Fremgangsmåde til nedlukning af en brønd